Corvus Pharmaceuticals Inc. (CRVS) Upgraded to Hold by Zacks Investment Research
According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “
A number of other research analysts have also weighed in on the company. Credit Suisse Group AG restated a buy rating and issued a $25.00 target price on shares of Corvus Pharmaceuticals in a report on Tuesday, September 27th. Cantor Fitzgerald set a $23.00 target price on Corvus Pharmaceuticals and gave the company a buy rating in a report on Saturday, August 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $21.60.
Corvus Pharmaceuticals (NASDAQ:CRVS) opened at 16.37 on Monday. Corvus Pharmaceuticals has a one year low of $9.63 and a one year high of $17.77. The firm’s market capitalization is $342.28 million. The firm has a 50-day moving average price of $14.88 and a 200-day moving average price of $14.00.
Institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Corvus Pharmaceuticals during the first quarter worth about $174,000. BlackRock Group LTD purchased a new position in Corvus Pharmaceuticals during the first quarter worth about $1,740,000. Jennison Associates LLC boosted its position in Corvus Pharmaceuticals by 22.9% in the second quarter. Jennison Associates LLC now owns 570,481 shares of the company’s stock worth $8,067,000 after buying an additional 106,349 shares during the last quarter. Arrowgrass Capital Partners US LP purchased a new position in Corvus Pharmaceuticals during the first quarter worth about $1,668,000. Finally, HBK Investments L P purchased a new position in Corvus Pharmaceuticals during the first quarter worth about $1,740,000. Institutional investors and hedge funds own 82.91% of the company’s stock.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.
Receive News & Stock Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.